

## Outcomes of kidney transplantation in patients with Fabry disease: real world experience

Oana R. Ailioaie, MD, PhD,<sup>1,4</sup> Iulia Jurca-Simina MD, PhD,<sup>1</sup> Oana Atanasiu, MD,<sup>1</sup> Lavinia M Bernea, MD,<sup>1</sup> Audrey Cordier,<sup>1</sup> Jean-Pierre Rabes, PhD,<sup>2,3</sup> Dominique P. Germain, MD, PhD.<sup>1,4</sup>  
<sup>1</sup> French Referral Center for Fabry disease, Division of Medical Genetics, Raymond Poincaré Hospital, APHP Paris Saclay, France. <sup>2</sup> Laboratory of Molecular Genetics, Ambroise Paré Hospital, APHP Paris Saclay, <sup>3</sup> Laboratory of Biochemistry, Raymond Poincaré Hospital, APHP Paris Saclay, <sup>4</sup> Division of Medical Genetics, University of Versailles, Montigny le Bretonneux

### Introduction:

Fabry disease (FD) (OMIM #301500) is an X-linked genetic disorder of glycosphingolipid metabolism. Renal involvement is one of the major features of FD. Data on patients with FD and kidney transplant are scarce in the literature.

### Methods:



Fifteen patients with classic FD (80% males) were treated in the French Referral Center for Fabry disease ([www.centre-geneo.com](http://www.centre-geneo.com)) for a mean post-transplant follow-up of 12.6 years (SD ± 8.2). Mean age was 54.7 years (± 8.9). All patients were treated by enzyme replacement therapy (ERT).

### Results:

Patient survival was 91.7% at 5 years and 82% at 10 years. Two patients died of cardiovascular causes and one from cancer. Graft survival was 93.4% at 5 years and 82% at 10 years. The mean glomerular filtration rate estimated by the CKD-EPI formula was 63.2 ml/min/1.73 m<sup>2</sup> (± 24.3), mean urinary protein to creatinine ratio was 0.28 g/g (± 0.16).

Immunosuppressive treatment comprised tacrolimus (70%), cyclosporine A (20%), mycophenolate mofetil (64%), azathioprine (18%) and corticosteroids (50%). Mean duration of ERT post-transplantation was of 14.4 years (SD± 6,3).

All females who needed kidney transplant had unfavorable skewed X chromosome inactivation. Amenable mutations were present in 33% of patients. One patient switched to migalastat after 13 years of ERT.



**Conclusion:** Kidney transplant in association with continued ERT appears generally favorable in patients with FD with good patient and graft survival, stabilized renal function and absence of proteinuria.